Results 181 to 190 of about 1,977,916 (307)

Pharmacist Intervention Models in Drug–Drug Interaction Management in Prescribed Pharmacotherapy [PDF]

Ivana Samardžić, Ivana Marinović, Iva Marović, Nikolina Kuča, Vesna Bačić Vrca, Ivana Samardžić, Ivana Marinović, Iva Marović, Nikolina Kuča, Vesna Bačić Vrca   +9 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Host–Pathogen Interaction Mapping in Drug-Resistant Tuberculosis: A Systems Biology Framework for Dual Therapeutic Targeting [PDF]

Onwu Daniel Ocha, Anmol Singh, Yashi Bajpai, Akinlamilo Adeyemi Sunday, Adele Habiganuchi, Felix Oladunjoye Ibikunle   +5 more
openalex   +1 more source

Interplay between RNA‐protein interactions and RNA structures in gene regulation

FEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko, Mauro Scaravilli, Minna‐Liisa Änkö   +2 more
wiley   +1 more source

Drug-drug interactions: A descriptive analysis of FDA adverse event reporting system. [PDF]

Medicine (Baltimore)
Alahmari A, Fatani S, Ahmed N.
europepmc   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

FEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel, Caroline Wozniak, Aya Sabri, Ben Haddad, Brooke Lopo, Alvaro Cobos, Sarah Sarofim, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evans   +9 more
wiley   +1 more source

Factors associated with drug-drug interactions involving citalopram in the UK Biobank. [PDF]

BJPsych Open
Laplace B, Wong WLE, Menchetti M, De Ronchi D, Fusar-Poli P, Fanelli G, MNESYS – Mood and Psychosis Sub-Project (Spoke 5), Serretti A, Lewis CM, Fabbri C.   +9 more
europepmc   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants. [PDF]

Clin Transl Sci
Chang J, Kim A, Humeniuk R, Shaik NA, Winter H, Peng CC, Xiao D, Abdelghany M, Llewellyn J, Davies S, Golden K, Chen S, Hyland RH, Caro L.   +13 more
europepmc   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source